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The aim of this study was to evaluate serum midkine (S-MK) concentrations as a prognostic tumour marker in oral squamous cell
carcinoma (OSCC). We measured S-MK concentrations in patients with OSCC and healthy volunteers. In addition, we performed
real-time quantitative reverse transcription–PCR analysis and immunohistochemistry with fresh tumour samples. To determine
whether S-MK concentrations have prognostic value, we performed survival analyses with clinical information by using the log-rank
test. Serum midkine concentrations were significantly higher in patients with OSCC than in healthy controls (Po0.001). Serum
midkine concentrations were also significantly increased in early-stage OSCC compared with those of healthy individuals (Po0.001).
In addition, immunohistochemistry allowed identification of overexpressed MK protein in OSCC tissues. MK mRNA showed higher
expression in OSCC samples compared with normal mucosal samples. Patients in high S-MK groups showed a significantly lower
5-year survival rate compared with patients in low S-MK groups (Po0.05). The increased S-MK concentrations in early-stage OSCC
were strongly associated with poor survival. Serum midkine concentrations may thus be a useful marker not only for cancer screening
but also for predicting prognosis of OSCC patients.
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Oral cancer is one of the common types of human cancer (Petersen,
2003; Jemal et al, 2006). The survival rate for patients with oral cancer
has not yet improved, despite better diagnostic techniques and
innovations in treatments. Improved survival of patients with oral
cancer requires better techniques for the prediction of prognosis. Oral
squamous cell carcinoma (OSCC), the most common of several types
of oral cancers, does not have a good prognosis. Several researchers
have studied the usefulness of tumour-associated antigens for primary
diagnosis of OSCC, but no tumour markers have given a precise
prediction of prognosis (Tsutsui et al, 1993; Krimmel et al, 1998).
Midkine (MK), a heparin-binding growth factor, is expressed
intensely during the midgestation period and its expression
becomes generally weak in adults (Kadomatsu et al, 1988;
Muramatsu, 2002). Midkine has various biological activities such
as neuronal survival, tissue repair, and carcinogenesis. Midkine,
which has neuroprotective activity and neurite extension (Michi-
kawa et al, 1993; Owada et al, 1999), expresses strongly in cerebral
infarct (Yoshida et al, 1995) and Alzheimer’s disease (Yasuhara
et al, 1993; Salama et al, 2005). Midkine promotes the migration of
inflammatory cells, specifically macrophages and neutrophils
(Takada et al, 1997; Horiba et al, 2000). With these activities,
MK expression increases at intraperitoneal adhesions after surgery
(Inoh et al, 2004) and cardiac remodelling after myocardial
infarction (Obama et al, 1998; Horiba et al, 2006). In addition, MK
plays an important role in carcinogenesis. Midkine expression in
various malignant tumours is higher than that in normal tissues
(Garver et al, 1993, 1994; Konishi et al, 1999; Ye et al, 1999).
Midkine protein expression was reported to be correlated with
poor prognosis in patients with neuroblastomas (Nakagawara et al,
1995), astrocytomas (Mishima et al, 1997), pancreatic head
carcinomas (Maeda et al, 2007), or gastrointestinal stromal
tumours (Kaifi et al, 2007). In addition, because MK protein is a
plasma-secreted protein, MK levels in blood may increase in
patients with malignant diseases. Enzyme-linked immunoassay
(EIA) has allowed measurement of MK levels in blood, and
increased blood MK levels have been reported in patients with
malignant tumours, including hepatocellular carcinoma (Mura-
matsu et al, 1996), gastric carcinoma, and lung carcinoma
(Ikematsu et al, 2000). These reports suggest that MK in blood
may have the potential to become a very useful tumour marker.
Recent studies have found increased preoperative S-MK concen-
trations in patients with oesophageal squamous cell carcinoma
(Shimada et al, 2003). In addition, higher plasma MK concentra-
tions in patients with neuroblastoma were strongly correlated with
poor survival (Ikematsu et al, 2003). Midkine levels in blood may
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sthus become a useful tumour marker for predicting prognosis of
cancer patients. However, no studies have focused on the
correlation between S-MK expression and OSCC.
In this study, we evaluated clinicopathological data and analysed
S-MK concentrations in 60 patients with OSCC and 134 healthy
volunteers. We used a novel automated fluorescent-enzyme
immunoassay (FEIA) system for this analysis. In addition, we
compared the expression of MK protein in OSCC tissues and
normal mucosal tissues by means of immunohistochemistry and
real-time polymerase chain reaction (PCR).
MATERIALS AND METHODS
Patients and healthy volunteers
A total of 60 patients with primary OSCC who were treated at the
Department of Oral and Maxillofacial Surgery (Kumamoto
University Hospital), between 1999 and 2004 were studied. We
excluded patients who presented with distant metastases and all
patients who underwent radical treatments. Fifty-three patients
had surgery with more than 10mm resection margins and no
microscopic residual tumour, and of those, 36 patients underwent
preoperative chemoradiotherapy. Seven patients underwent radi-
cal chemoradiotherapy and we confirmed no residual tumour and
no local recurrence. Of the 60 OSCC patients, 37 were males and 23
were females, with a mean age of 66.8±11.4 years (median 67;
range 27–92). All patients were staged according to the 1997 UICC
TNM Classification of Malignant Tumors (Sobin and Wittekind,
2002). Clinicopathological data, including age, sex, blood data
(leukocyte count and platelet count), tumour size, nodal status (N
factor; cervical lymph node metastasis), degree of differentiation of
OSCC, and prognosis, were obtained from patient files. Serum
samples were collected from all patients; biopsy tissue specimens
were obtained from 52 patients before treatment.
We also collected samples from healthy volunteers who did not
have any disorders, such as liver dysfunction and rheumatoid
arthritis, after they underwent medical check-ups at Kumamoto
University Hospital. In total, we evaluated 134 serum samples and
27 normal oral mucosal specimens, which we excised surgically
when we extracted teeth. Of the 134 healthy volunteers, 73 were
males and 61 were females, with a mean age of 63.8±11.0 years
(median 65; range 20–92). Twenty-seven healthy volunteers
(20.1%) and 16 OSCC patients (26.7%) had a smoking habit.
Between OSCC patients and healthy volunteers, the smoking habit
nearly matched. All subjects gave their informed consent.
All serum samples were collected, by means of venipuncture,
from patients and volunteers after they gave informed consent.
Venous blood was allowed to clot for 30min at room temperature
and was then centrifuged for 10min at 3000r.p.m. Serum samples
were collected from OSCC patients before treatment. Serum
samples and biopsy specimens were stored at –801C until MK
assays and real-time PCR. The remaining tumour materials
were fixed in 10% formalin for immunohistochemistry before
processing.
EIA for MK
The EIA MK assay is a two-site immunoenzymometric assay,
requiring 50ml of serum sample, which was performed auto-
matically using an immunoassay analyser, AIA-600II (Tosoh
Corporation, Tokyo, Japan). Midkine in a sample was simulta-
neously reacted with mouse anti-midkine monoclonal antibody
(SC-2) immobilised on magnetisable beads and with alkaline
phosphatase-labelled mouse anti-midkine monoclonal antibody
(SC-4) to form a sandwich structure. After 10min of incubation at
371C, the beads were washed to remove unbound materials. A
fluorogenic substrate, 4-methylumbelliferyl phosphate, was added
for the enzyme-substrate reaction at 371C for 5min. The rate of
fluorescence of converted 4-methylumbelliferone was directly
proportional to the MK concentration in the samples.
RNA isolation and real-time PCR
Total RNA was extracted by using the RNeasy Mini Kit (Qiagen,
Hilden, Germany) and treated with the RNase-Free DNase Set
(Qiagen) according to the manufacturer’s instructions. Total RNA
was quantified with a NanoDrop ND-1000 (NanoDrop Technolo-
gies, Wilmington, DE, USA) spectrophotometer and software
program. Total RNA (0.5mg) in samples was reverse transcribed to
complementary DNA (cDNA) by using the ExScript RT reagent
(Takara Bio Inc., Otsu, Japan), according to the manufacturer’s
protocol. All PCR reactions were performed by using the Light-
Cycler 480 System (Roche Diagnostics, Basel, Switzerland) with a
LightCycler 480 SYBR Green I Master kit (Roche Diagnostics). A
reaction mixture was added to 2.0ml of cDNA for each sample. The
reaction mixture contained the following components: 6.0mlo f
water, 1ml of forward primer (0.5mM), 1ml of reverse primer
(0.5mM), and 10mlo f2  Master mix. The primers used for real-
time PCR were as follows: MK forward 50-AGATGCAGCACCGAG
GCT-30, MK reverse 50-CTTTCTTTTTGGCGACCG-30; b2-micro-
globlin (b2M) forward 50-CGGGCATTCCTGAAGCTGA-30, and
b2M reverse 50-GGATGGATGAAACCCAGACACATAG-30.
The b2M gene was chosen for normalisation of data. Each
reaction was performed under the following conditions: initialisa-
tion for 10s at 951C and then 45 cycles of amplification, with 5s at
951C for denaturation and 20s at 601C for annealing and
elongation. After amplification, the temperature was slowly raised
to above the melting temperature of the PCR product to measure
fluorescence and thereby to determine the melting curve. In
addition, to ensure RNA quality, several preparations were
subjected to analysis of expression using the Hitachi SV1210
microchip electrophoresis system (Hitachi Electronics Engineering
Company, Tokyo, Japan). A standard curve was plotted for each
primer probe established by using serial dilution of pooled cDNA
from tissues. All standards and samples were analysed in triplicate.
Immunohistochemistry
To detect MK in OSCC samples, we performed immunohisto-
chemical analysis with two monoclonal MK antibodies: IP-10, with
an epitope in the N-terminal half of the MK fragment, and IP-14,
reacting with the C-terminal half of the MK fragment. The primary
antibodies IP-10 and IP-14 were generated by Cell Signals Inc.
(Yokohama, Japan). Paraffin-embedded 4-mm-thick sections were
prepared, deparaffinised in xylene, and rehydrated in graded
alcohols. Endogenous peroxidase activity was blocked by immer-
sing sections in 0.3% hydrogen peroxide in methanol for 30min,
and antigen retrieval was performed by a 15-min microwave
pretreatment in citrate buffer (pH 6.0, 0.01moll
 1). After being
incubated with Protein Block Serum-Free (Dako, Glostrup, Den-
mark), sections were incubated overnight at 41C with mouse
monoclonal antibodies (IP-10 at 1:25; IP-14 at 1:100). After
incubation with antimouse labelled polymer (EnVision
þ System
HPR; Dako) for 30min at room temperature, 3,30-diaminobenzi-
dine was used as the chromogen. Sections were immunohisto-
chemically stained and were then counterstained with hematoxylin
to enhance nuclear detection.
Statistical analysis
The normality of the data was first assessed using the Shapiro–
Wilks test. Data were then evaluated using Student’s t-test and an
analysis of variance (normal distributed data) or by the Kruskall–
Wallis test (non-normal data). Regression analysis was done by
simple regression on S-MK concentrations to leukocyte or platelet.
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operating characteristic (ROC) curves were constructed by
calculating the sensitivities and specificities for cutoff values.
The optimal cutoff values were selected on the basis of the
extreme upper left points of the ROC curves. Survival curves were
plotted by using the Kaplan–Meier method and analysed with
the log-rank test for univariate analysis. All analyses were
performed with the JMP (version 5.0.1; SAS Institute Japan,
Tokyo, Japan). P-values of less than 0.05 were regarded as
statistically significant.
RESULTS
S-MK concentration and its correlation with prognosis in
OSCC
We determined S-MK concentrations in samples from 60 OSCC
patients and 134 healthy volunteers. The mean (±s.d.) S-MK
concentration was 885.9±465.0pgml
 1 for the OSCC patients and
419.1±97.9pgml
 1 for the healthy subjects. Serum midkine
concentrations for the OSCC patients were significantly higher
than those for healthy volunteers (Figure 1). To examine the
usefulness of this marker protein, a cutoff point was determined
for each set of values, by using a ROC curve, under the condition of
specificity equal to 99.3%. With a cutoff value of 650, 66.7% of the
OSCC patients had S-MK values that were positive predictive
markers. As Table 1 shows, S-MK concentrations in patients and
healthy subjects older than 60 years were significantly higher
compared with those in patients and healthy subjects younger than
60 years, respectively. We compared S-MK concentrations in
healthy volunteers and OSCC patients under 60 and over 60 years
old. Serum midkine concentrations of OSCC patients were
significantly higher than those in healthy volunteers over 60 years
old (965.8±505.5 and 456.3±119.2pgml
 1, respectively). More-
over, in the analysis of both groups under the age of 60 years old,
the concentrations in OSCC patients were significantly higher than
those in healthy volunteers (645.9±160.8 and 345.3±93.6pgml
 1,
respectively). We concluded from these analyses that, indepen-
dently from the ages, S-MK concentrations in OSCC patients were
significantly higher than those in age-matched healthy volunteers.
We also studied S-MK concentrations in relation to clinicopatho-
logical parameters (sex, age, smoking habit, clinical stage, tumour
size, cervical lymph node metastasis, degree of differentiation of
OSCC, and prognosis) in OSCC patients (Tables 1 and 2). However,
we found no correlation between S-MK and sex, tumour size,
cervical lymph node metastasis, or degree of differentiation of
OSCC. Although S-MK concentrations showed no increasing
tendency related to clinical stage, concentrations were significantly
elevated in all stages in OSCC compared with those in healthy
volunteers (stage I, III, IV; Po0.001, stage II; Po0.01) (Figure 2).
We measured leukocyte and platelet counts to examine the
influence of S-MK concentrations. With simple regression analysis,
a relationship was not found between S-MK concentrations and the
numbers of leukocytes or platelets (leukocytes r¼0.03 P¼0.80;
platelets r¼0.02 P¼0.90). We also measured the MK concentra-
tion in plasma in 60 OSCC patients and 91 healthy volunteers.
Plasma MK (P-MK) concentrations in OSCC patients and healthy
volunteers were 783.6±286.1 and 404.2±89.3pgml
 1, respec-
tively. Oral squamous cell carcinoma patients had significantly
higher P-MK concentrations than did healthy volunteers
(Po0.0001).
In our investigation of the relationship between S-MK concen-
trations and prognosis, we divided OSCC S-MK concentrations
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Figure 1 Serum midkine concentrations for healthy volunteers and
OSCC patients. Healthy volunteers (n¼134; 80 males and 54 females),
and OSCC patients (n¼60; 38 males and 22 females). Statistical
significance was evaluated using Student’s t-test. *Po0.001.
Table 1 Characteristics and S-MK concentrations for healthy volunteers and OSCC patients
Healthy volunteers OSCC patient
Clinical parameters Number
Mean±s.d. S-MK
concentrations (pgml
 1) P-value Number
Mean±s.d. S-MK
concentrations (pgml
 1) P-value P-value
Mean S-MK concentration 134 419.1±97.9 60 885.9±465.0 o0.001
Sex
Male 73 407.0±21.4 0.173 37 949.9±514.7 0.178 o0.001
Female 61 433.5±98.1 23 782.8±358.3 o0.001
Mean age±s.d. 63.8±11.0 66.8±11.4 0.075
Age (years)
o60 45 345.3±93.6 0.006 15 645.9±160.8 0.020 o0.001
X60 89 456.3±119.2 45 965.8±505.5 o0.001
Smoker 20.1% 26.7% 0.318
No-smoker 134 418.2±103.0 0.831 44 851.0±450.1 0.340 o0.001
Smoker 27 422.7±75.8 16 981.8±506.5 o0.001
OSCC¼oral squamous cell carcinoma; S-MK¼serum midkine.
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 1 (n¼40) or
lower than 650pgml
 1 (n¼20). The lower S-MK concentration
group had a significantly greater 5-year survival rate than did the
higher S-MK concentration group (82.9 vs 56.6%; Po0.05)
(Figure 3). The median survival time of OSCC patients with high
S-MK groups was 62 months, but the survival rate in low S-MK
groups was not below 50%, whereas the average observation
period after radical treatment was 69.2 months. We observed
no significant relationship between 5-year survival rate and
age. However, as Table 2 shows, clinical stage, tumour size, and
cervical lymph node metastasis were significantly related to 5-year
survival rate.
MK mRNA levels in OSCC
To examine the relative expression of the MK gene in OSCC
samples, we used real-time PCR to determine MK mRNA levels in
60 samples from OSCC patients and 28 samples from healthy
volunteers. Midkine mRNA levels were significantly higher in
OSCC tissues than in normal mucosal tissues (0.28 vs 0.15 Po0.05)
(Figure 4). However, MK mRNA expression in each OSCC tissue
specimen was not significantly associated with S-MK concentra-
tion (data not shown).
Table 2 Relationship between clinical parameters and S-MK concentrations or 5-year survival rate in patients with OSCC
Clinical parameters No. of patients Mean±s.d. S-MK concentrations (pgml
 1) P-value 5-year survival rate (%) P-value
Sex
Male 37 949.9±514.7 0.178 71.9 0.141
Female 23 782.8±358.3 56.7
Age (years)
o60 15 645.9±160.8 0.020 78.3 0.449
X60 45 965.8±505.5 61.9
Clinical stage
I 7 931.2±443.3 0.977 100 0.003
II 17 864.8±559.7 92.3
III 7 839.8±317.0 66.7
IV 29 900.5±464.2 44.5
Tumour size (mm)
o40 35 845.8±461.7 0.434 85.2 o0.001
X40 25 942.0±473.2 41.5
Cervical lymph node metastasis (N factor)
N( ) 35 900.1±523.8 0.782 82.5 o0.001
N(+) 25 865.9±377.1 42.4
Differentiation of OSCC
Well 36 822.4±453.2 80.2
Moderately 17 943.0±367.2 0.327 42.1 0.057
Poorly 7 1095.1±697.7 51.4
S-MK concentration
o650 20 — 82.9 0.045
X650 40 56.6
OSCC¼oral squamous cell carcinoma; S-MK¼serum midkine.
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Figure 2 Serum midkine concentrations at each clinical stage in OSCC
patients and in healthy volunteers. Statistical significances were evaluated
using Student’s t-test. *Po0.001, **Po0.01.
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Figure 3 Survival of OSCC patients with high or low S-MK concentra-
tions. Closed squares: patients with S-MK concentrations of X650pgml
 1
(n¼40) had a survival rate of 56.6%. Closed circles: patients with S-MK
concentrations of o650pgml
 1 (n¼20) had a survival rate of 82.9%.
Statistical significances were evaluated using log-rank test. *Po0.05.
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Immunoreactive MK was localised in cancer cell cytoplasm. Out
of 52 OSCC samples evaluated with IP-10 antibody, 45 were
immunoreactive; with IP-14 antibody, 43 samples also showed a
positive reaction. However, differences in reactivity – chromatic
strength and localisation of staining – were noted with the IP-10
and IP-14 antibodies. Recognition of tumour cells by IP-10 was
greater, and only IP-14 was immunoreactive with glandular duct
(Figure 5).
DISCUSSION
Our study produced two important findings. First, even though
S-MK concentrations were not related to clinical stage, tumour
size, and cervical lymph node metastasis, S-MK concentration
offers promise as a novel tumour marker of prognosis in OSCC.
Serum midkine concentrations will allow us to predict prognosis
because, in the presence of highly elevated concentrations, we
would use a larger surgically margin when removing a tumour
and would perform chemotherapy and/or radiotherapy before or
after the operation with better results. Midkine has been well
documented to promote various activities related to oncogenesis
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Figure 4 MK mRNA expression for healthy individuals and OSCC
patients. Healthy volunteers (n¼28) and OSCC patients (n¼60) were
subjected to this study. b2-Microgloblin was used to normalise the data as
described in the text. Statistical significance was evaluated using Student’s
t-test. *Po0.05.
IP-10 IP-14
Figure 5 Immunohistochemistry with anti-MK antibody in OSCC and glandular duct samples. The biopsy specimen was obtained from a 59-year-old man
with OSCC (T2N2bM0, stage IV). (A), (C), and (E) Immunohistochemistry with IP-10 antibody. (B), (D), and (F) immunohistochemistry with IP-14
antibody. (A–D) The OSCC tissues and (E and F) glandular ducts. (A and B) original magnification,  40, scale bar¼1mm; (C and D) original
magnification,  200, scale bar¼200mm; and (E and F) original magnification,  100, scale bar¼500mm.
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sand tumour progression, including cell migration (Takada et al,
1997), angiogenic functions (Choudhuri et al, 1997), mitogenesis
(Muramatsu and Muramatsu, 1991), and antiapoptosis (Owada
et al, 1999). Midkine can also give cancerous cells a growth
advantage through antiapoptotic activity. Qi et al (2000) observed
that MK protein rescued G401 cells, a Wilms’ tumour cell line,
from cisplatin-induced apoptosis by upregulation of Bcl-2. Mirkin
et al (2005) reported that increased MK expression exerted a
significant cytoprotective effect against doxorubicin in drug-
sensitive cells. They suggested that MK indirectly mediates
acquired drug resistance to protect neighbouring drug-sensitive
cells and contributes to the development of resistance to
chemotherapeutics. In 40 patients who underwent an operation
and chemotherapy, S-MK concentrations tended to be higher in
the group with recurrence and/or metastasis than in the group
without recurrence or metastasis (Figure 6). We confirmed the
belief that MK directly or indirectly aids survival of cancer
cells through antiapoptosis and provides cytoprotection against
chemotherapy and radiotherapy. Takei et al (2006) reported that
a combined therapy involving MK small interfering RNA and
Paclitaxel significantly enhanced anticancer activity or maintained
the effective anticancer activity of Paclitaxel. To inhibit the
secretion of MK may be a novel therapy against drug-resistant
cancers. In addition, MK protein expression in OSCC cases was
reported to be significantly correlated with the expression of
vascular endothelial growth factor (VEGF) (Ruan et al, 2007), and
S-MK concentration was correlated with serum levels of VEGF-C
(Krzystek-Korpacka et al, 2007). Expression of VEGF was also
significantly correlated with prognosis in OSCC (Uehara et al,
2004). In these previous results, MK may be related to a prognosis
through the activation of VEGF. However, it was reported that MK
downregulated VEGF-A-induced neovascularisation and vascular
permeability in a recent study (van der Horst et al, 2008). The
involvement of MK in tumour angiogenesis warrants further
investigation and should include a study of VEGF.
Second, we believe that S-MK concentration can become a tool
for screening of OSCC. Serum midkine concentrations in patients
with early-stage OSCC were significantly higher than those in
healthy individuals. This result suggests that S-MK concentration
may assist in the early detection of not only OSCC but also other
tumours. We measured P-MK concentrations to investigate
whether MK leaks from platelets in blood coagulation and an
anticoagulant have an influence on the expression of MK. In P-MK
concentrations, those values were more elevated in OSCC patients
than in healthy volunteers as did in S-MK concentrations. In
addition, P-MK concentrations in OSCC patients in the early stage
were significantly higher than those in healthy individuals.
Platelets and leukocytes in OSCC patients did not relate to the
expression of MK. These results suggest that P-MK and S-MK
concentrations are useful for early diagnosis of oral cancer.
However, concerning the collection of plasma samples, we could
not collect those for a long period. As the collected samples
were all within 4 years after the surgery, we could not calculate
the 5-year survival rate. In reports on other tumours, such as
neuroblastoma (Ikematsu et al, 2003), oesophageal cancer
(Shimada et al, 2003), and gastric cancer (Obata et al, 2005),
serum or plasma MK concentrations were significantly elevated.
Because MK is a plasma protein, serum or plasma MK concentra-
tions can be elevated in various types of cancer. As we
demonstrated here, an automated FEIA system may be useful in
screening for cancer in a large number of samples in a short time.
In both OSCC patients and healthy subjects, S-MK concentra-
tions older than 60 years were significantly higher compared with
those younger than 60 years. These analyses suggest that ageing
may influence S-MK concentrations. On the basis of the past
reports about MK expression in ageing-related diseases, it is
natural to consider that expression of MK is elevated in the
presymptomatic stages of diseases, such as asymptomatic cerebral
infarction, asymptomatic ischemic heart diseases, and a patho-
logical prestage of Alzheimer’s disease.
Figures 4 and 5 demonstrated, by means of immunohistochem-
istry and mRNA MK analysis, that MK protein was overexpressed
in OSCC tissues compared with healthy tissue from volunteers.
However, MK mRNA expression in OSCC tissue specimens was not
significantly associated with S-MK concentrations. Serum midkine
concentrations were previously reported to be associated with MK
protein expression in oesophageal cancer cells (Shimada et al,
2003), and the 5-year survival rate of a group with high MK
expression in OSCC tissue was lower than that of a group with low
MK expression (Ruan et al, 2007). These results suggest that MK
overexpression in OSCC tissues may promote high concentrations
of S-MK. Expression of MK may be localised in cancer tissues,
because RNA was extracted from some cancer tissues. However, we
found no relationship between tumour size and S-MK concentra-
tions and no correlation between MK mRNA expression and 5-year
survival rates (data not shown).
Expression of a truncated form of MK (t-MK) mRNA, which
lacks exon 3 encoding the N terminus, has been well documented
in various tumours, including colon (Miyashiro et al, 1996), breast
(Miyashiro et al, 1997), gastric (Aridome et al, 1998), and liver and
kidney (Tao et al, 2007). Therefore, we immunostained OSCC
tissues with IP-14 antibody, which had an epitope in the
C-terminus, and IP-10 antibody, which had an epitope in the
N-terminus. One might expect that IP-14, which recognised both
the full-length and truncated forms of MK, would show a stronger
reaction in carcinoma than IP-10, which did not cross-react with
t-MK. However, our results did not support this expectation. IP-14
reactivity was weaker than IP-10 reactivity (Figure 5). Our result
agrees with the report of Nobata and colleagues (Nobata et al,
2005) that the C-terminus can easily be affected by protease and
that t-MK antibody has a low affinity for the C-terminus.
Moreover, we first believed that IP-10 would strongly react with
MK functioning in protection of the N-terminal part of the
molecule from proteolytic degradation (Matsuda et al, 1996).
However, glandular ducts stained only with IP-14 antibody. This
finding indicates that t-MK may be expressed in normal salivary
glands, although previous studies reported that t-MK was not
detected in noncancerous tissues. Studies to clarify the localisation
of t-MK are in progress. On the basis of these results, we analysed
S-MK concentrations by using SC2 and SC4 antibodies, which had
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Figure 6 Serum midkine concentrations in the group with no recurrence
or metastasis and the group with recurrence and/or metastasis. Statistical
significance was evaluated using Student’s t-test. *P¼0.17.
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sepitopes in the N-terminus, as does the IP-10 antibody. Even
though these antibodies did not react with t-MK, they could detect
full-length MK, and the sandwich ELISA performed with these two
antibodies was specific and useful for cancer screening and
predicting the prognosis of OSCC patients.
In conclusion, S-MK concentrations in OSCC patients were
associated with prognosis (5-year survival) but not with conven-
tional prognostic factors such as clinical stage, tumour size, and
cervical lymph node metastasis. Midkine expression in blood and
cancer tissues is indicative of a strong relationship with malignant
potential, and high MK expression suggests a bad prognosis. These
studies may lead to trials to inhibit MK expression by using
MK antibody and small interfering RNA. The study of MK may
elucidate problems of anticancer drug resistance in various cancers
and contribute to improvement in prognosis.
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